Dose Blocked-randomized, Double-blind, Placebo Controlled, Single Dose, Dose-escalation Study to Investigate the Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 After Intravenous Administration in Healthy Male Volunteers
Latest Information Update: 05 Apr 2021
Price :
$35 *
At a glance
- Drugs Burfiralimab (Primary)
- Indications Alcoholic hepatitis; COVID-19 pneumonia; Hepatitis B; Non-alcoholic steatohepatitis; Pneumonia; Psoriasis; Scleroderma
- Focus Adverse reactions; First in man
- Sponsors ImmuneMed
- 17 Mar 2021 Results presented at the 122nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 09 Mar 2021 Status changed from recruiting to completed.
- 30 Nov 2018 Planned End Date changed from 1 Aug 2019 to 1 Oct 2019.